Free Trial
NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$2.69 +0.15 (+5.91%)
Closing price 04:00 PM Eastern
Extended Trading
$2.69 0.00 (0.00%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Codexis Stock (NASDAQ:CDXS)

Advanced

Key Stats

Today's Range
$2.52
$2.73
50-Day Range
$2.35
$3.10
52-Week Range
$1.90
$6.08
Volume
712,971 shs
Average Volume
881,942 shs
Market Capitalization
$242.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Hold

Company Overview

Codexis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

CDXS MarketRank™: 

Codexis scored higher than 66% of companies evaluated by MarketBeat, and ranked 339th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Codexis has a consensus price target of $11.00, representing about 319.0% upside from its current price of $2.63.

  • Amount of Analyst Coverage

    Codexis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Codexis' valuation and earnings.
  • Percentage of Shares Shorted

    6.24% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Codexis has recently increased by 12.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.24% of the outstanding shares of Codexis have been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Codexis has recently increased by 12.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Codexis has a news sentiment score of 1.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.90% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDXS Stock News Headlines

Codexis Weighs ECO Scale As Cash Runway Tightens
Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
Craig-Hallum Remains a Buy on Codexis (CDXS)
Codexis Inc. (CDXS) Stock Price Today - WSJ
Codexis: Q2 Earnings Snapshot
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $4.77 on January 1st, 2025. Since then, CDXS shares have decreased by 45.0% and is now trading at $2.6250.

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The biotechnology company earned $15.33 million during the quarter, compared to analysts' expectations of $14.18 million. Codexis had a negative trailing twelve-month return on equity of 105.83% and a negative net margin of 113.67%.
Read the conference call transcript
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/13/2025
Today
10/06/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDXS
CIK
1200375
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+335.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.28 million
Net Margins
-113.67%
Pretax Margin
-113.61%
Return on Equity
-105.83%
Return on Assets
-46.06%

Debt

Debt-to-Equity Ratio
0.71
Current Ratio
5.82
Quick Ratio
5.70

Sales & Book Value

Annual Sales
$59.35 million
Price / Sales
3.84
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.82 per share
Price / Book
3.08

Miscellaneous

Outstanding Shares
90,270,000
Free Float
88,552,000
Market Cap
$227.93 million
Optionable
Optionable
Beta
2.50
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners